专栏manbetx3.0 社会

Navigating Tensions in China's Centralized Drug Procurement
如何从公司运作洞察关于集采的争议

Amidst public concerns over drug efficacy, China's healthcare system faces scrutiny as doctors and regulatory bodies clash over centralized procurement practices. The debate highlights inherent tensions between cost control and quality assurance, underscoring the need for balanced oversight in healthcare policy.
刘远举:医生说药不好,医保部门说药好,在有限的信息下,普通人该如何理解其中的争议呢?
This English translation is AI-generated and provided for reference only.

In response to claims that drugs from centralized procurement are ineffective, such as "blood pressure not lowering" and "anesthetics not working," the National Healthcare Security Administration recently issued a new statement. While it's good to have a response, this one came too quickly and doesn't match the amount of work required. Moreover, it lacks traceable, real-name endorsements, and even the journalist conducting the interview wasn't named. Therefore, further responses to public concerns are indeed necessary.

针对集采药“血压不降、麻药不睡”等说法,国家医保局近日给出了最新回应。有回应很好,但这个回应太快,与其需要的工作量不相符。而且缺乏可追溯的实名背书,连采访的记者都没署名。所以的确还需要进一步回应公众关切。

您已阅读5%(626字),剩余95%(11608字)包含更多重要信息,订阅以继续探索完整内容,并享受更多专属服务。
版权声明:本文版权归manbetx20客户端下载 所有,未经允许任何单位或个人不得转载,复制或以任何其他方式使用本文全部或部分,侵权必究。

远观近思

刘远举,重庆人,先学理工科再学manbetx20客户端下载 学,从事过咨询行业,现为自由撰稿人。关注时政、财经、科技,旨在探寻现象背后的事实与公正。文风理性、客观,且用人性的温度替换虚伪的中立。微博ID@刘远举。

相关文章

相关话题

设置字号×
最小
较小
默认
较大
最大
分享×